Charline Herrscher

Ms. Charline Herrscher


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
CHCharline Herrscher
Charline Herrscher
PRPhilippe Roingeard
Philippe Roingeard
EBEmmanuelle Blanchard
Emmanuelle Blanchard
Hepatitis B virus (HBV), an enveloped partially double-stranded DNA virus, is a widespread human pathogen responsible for more than 250 million chronic infections worldwide. Current therapeutic strategies cannot eradicate HBV due to the persistence of the viral genome in a special DNA structure (covalently closed circular DNA, cccDNA). The identification of sodium taurocholate co-transporting polypeptide (NTCP) as an entry receptor for both HBV and its satellite virus hepatitis delta virus (HDV) has led to great advances in our understanding of the life cycle of HBV, including the early steps of infection in particular. However, the mechanisms of HBV internalization and the host factors involved in this uptake remain unclear. Improvements in our understanding of HBV entry would facilitate the design of new therapeutic approaches targeting this stage and preventing the de novo infection of naïve hepatocytes. In this review, we provide an overview of current knowledge about the process of HBV internalization into cells.

1 June 2020 in Journal of Molecular Biology
Verified
Journal Article
Closed access
VRVirgile Rat
Virgile Rat
XPXavier Pinson
Xavier Pinson
FSFlorian Seigneuret
Florian Seigneuret
SDStéphanie Durand
Stéphanie Durand
CHCharline Herrscher
Charline Herrscher
HRHugues de Rocquigny
Hugues de Rocquigny

14 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CHCharline Herrscher
Charline Herrscher
SESébastien Eymieux
Sébastien Eymieux
CGChristophe Gaborit
Christophe Gaborit
Helene BlascoHelene Blasco
Helene Blasco
JMJulien Marlet
Julien Marlet
CHChristophe Hourioux
Christophe Hourioux
Since the start of the COVID-19 pandemic, many studies have investigated the humoral response to SARS-CoV-2 during infection. Studies with native viral proteins constitute a first-line approach to assessing the overall immune response, but small peptides are an accurate and valuable tool for the fine characterization of B-cell epitopes, despite the restriction of this approach to the determination of linear epitopes. In this study, we used ELISA and peptides covering a selection of structural and non-structural SARS-CoV-2 proteins to identify key epitopes eliciting a strong immune response that could serve as a biological signature of disease characteristics, such as severity, in particular. We used 213 plasma samples from a cohort of patients well-characterized clinically and biologically and followed for COVID-19 infection. We found that patients developing severe disease had higher titers of antibodies mapping to multiple specific epitopes than patients with mild to moderate disease. These data are potentially important as they could be used for immunological profiling to improve our knowledge of the quantitative and qualitative characteristics of the humoral response in relation to patient outcome.